Home Newsfeeds GT Biopharma Q3 EPS $(0.22) Down From $(0.17) YoY

GT Biopharma Q3 EPS $(0.22) Down From $(0.17) YoY

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.22) per share. This is a 29.41 percent decrease over losses of $(0.17) per share from the same period last year.

byMichael Horton

October 31, 2022

1 minute read

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.22) per share. This is a 29.41 percent decrease over losses of $(0.17) per share from the same period last year.

enVVeno Medical Successfully Passes Preliminary FDA Safety Review For The VenoValve U.S. Pivotal Study

By Benzinga Newsdesk

November 7, 9:46 AM

The Company submitted safety data for the first 20 patients enrolled in the ongoing SAVVE U.S. pivotal study for the VenoValve Following the initial safety data review by the FDA, the SAVVE study is cleared to continue

NVNO

GameStop NFT Marketplace Takes Two Days To Pass Coinbase NFTs In Sales Volume: Could Launch Be Underestimated By Market Experts?

By Chris Katje

July 15, 11:11 AM

Leading video game retailer GameStop Corp (NYSE: GME) has highlighted plans for an NFT marketplace as one of its key growth items moving forward. After a slight delay, the marketplace is live and putting up sales volume that is already ahead of a leading cryptocurrency platform.

COIN

Dayforce Sees Q1 Revenue $424M-$427M Vs $427.81M Est.; FY24 Revenue $1.72B-$1.73B Vs $1.74B Est.

By Benzinga Newsdesk

February 7, 11:19 AM

Business OutlookBased on information available as of February 7, 2024, Dayforce is issuing the following guidance for the first quarter and full year of 2024 as indicated below. Comparisons are on a year-over-year basis,

DAY